A rare form of leukemia known as TCF3::HLF-positive B cell acute lymphoblastic leukemia (B-ALL) sits among the most ...

In the past 25 years — from 2000 to 2024 — we have witnessed a revolution in the management, treatment, and outcome of what used to be the most lethal hematologic cancer: Philadelphia ...

In most cases, acute lymphoblastic leukemia (ALL) manifests as a de novo malignancy in previously healthy people. Risk factors for developing ALL include age older than 70 years and genetic disorders, ...

Supportive care aims to ensure that patients with acute lymphoblastic leukemia (ALL) derive the most benefit from ALL therapy despite the intensive treatments they undergo. Supportive care should be ...

At the recent American Society of Hematology annual meeting, researchers presented preclinical data examining how transdifferentiation between hematopoietic lineages -- driven by LMO2 expression and ...

Asparlas (calaspargase pegol-mknl) is a long-acting prescription injection medicine used for people with a certain type of blood cancer known as acute lymphoblastic leukemia (ALL). It is approved in ...

Abstract Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and despite cure rates exceeding 90% in children, it remains an important cause of morbidity and mortality in children ...

Acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) are types of blood cancer. Acute lymphoblastic leukemia is a fast-growing type of blood cancer. It happens when the body makes too ...

Patients with acute leukemia prioritize tiredness as the most important health dimension over cognition, differing from the general public's preferences. Informal caregivers report significant ...

Despite a host of checks and balances that usually prevent harmful genetic mutations, sometimes mistakes happen, with serious ...